Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2013	Feb. 28, 2014	Jun. 28, 2013
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Trading Symbol	MELA
Entity Registrant Name	MELA SCIENCES, INC. /NY
Entity Central Index Key	0001051514
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		47,755,791
Entity Public Float			$ 39,730,954

Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 3,783	$ 7,862
Accounts receivable (net of allowance of $46 and $0 as of December 31, 2013 and 2012, respectively)	57	180
Inventory (net of reserve $325 and $0 as of December 31, 2013 and 2012, respectively) (See Note 4)	5,631	676
Prepaid expenses and other current assets	880	965
Total Current Assets	10,351	9,683
Property and equipment, net (See Note 5)	3,691	7,350
Patents and trademarks, net	42	47
Deferred financing costs		106
Other assets	48	84
Total Assets	14,132	17,270
Current Liabilities:
Accounts payable (includes related parties of $33 and $60 as of December 31, 2013 and 2012, respectively)	1,479	1,850
Accrued expenses (includes related parties of $48 and $0 as of December 31, 2013 and 2012, respectively)	844	956
Deferred placement revenue	244	172
Warrant liability (See Note 10)	3,017
Other current liabilities	68	41
Total Current Liabilities	5,652	3,019
Long Term Liabilities:
Deferred placement revenue	64	132
Deferred rent	120	144
Total Long Term Liabilities	184	276
Total Liabilities	5,836	3,295
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity:
Preferred stock-$0.10 par value; authorized 10,000,000 shares: issued and outstanding: none
Common stock-$0.001 par value; authorized 95,000,000 shares: Issued and outstanding 47,501,596 and 32,204,720 shares at December 31, 2013 and 2012, respectively.	48	32
Additional paid-in capital	176,396	156,143
Accumulated deficit	(168,148)	(142,200)
Total Stockholders' Equity	8,296	13,975
Total Liabilities and Stockholders' Equity	$ 14,132	$ 17,270

Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Allowance for accounts receivable, current	$ 46	$ 0
Inventory, net of reserves	325	0
Accounts payable, related parties	33	60
Accrued expenses, related parties	$ 48	$ 0
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	47,501,596	32,204,720
Common stock, shares outstanding	47,501,596	32,204,720

Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Net revenues	$ 536	$ 278
Cost of revenue	4,341	2,042
Gross profit	(3,805)	(1,764)
Operating expenses:
Research and development	3,782	6,792
Selling, general and administrative	15,536	14,169
Impairment of long-lived assets	1,011
Total operating expenses	20,329	20,961
Operating loss	(24,134)	(22,725)
Other income (expenses):
Interest income	8	32
Interest expense	(564)
Change in fair value of warrant liability	(296)
Write-off of unamortized loan costs	(983)
Other income, net	21	20
Non operating income and expense	(1,814)	52
Net loss	$ (25,948)	$ (22,673)
Basic and diluted net loss per common share	$ (0.60)	$ (0.74)
Basic and diluted weighted average number of common shares outstanding	42,894,500	30,762,610

Statement of Stockholders' Equity (USD $) In Thousands, except Share data	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2011	$ 29,807	$ 30	$ 149,304	$ (119,527)
Beginning Balance, Shares at Dec. 31, 2011		30,308,000
Cashless exercise of options
Cashless exercise of options, Shares		12,000
Exercise of options	45		45
Exercise of options, Shares	61,796	21,000
Issuance of shares of common stock in connection with Public Offering (net of issuance costs)	5,308	2	5,306
Issuance of shares of common stock in connection with Public Offering (net of issuance costs), Shares		1,864,000
Share-based compensation expense	1,488		1,488
Net loss	(22,673)			(22,673)
Ending Balance at Dec. 31, 2012	13,975	32	156,143	(142,200)
Ending Balance, Shares at Dec. 31, 2012	32,204,720	32,205,000
Exercise of options	18		18
Exercise of options, Shares	18,059	18,000
Issuance of shares of common stock in connection with Public Offering (net of issuance costs)	15,725	11	15,714
Issuance of shares of common stock in connection with Public Offering (net of issuance costs), Shares		10,814,000
Issuance of shares of common stock and warrants in connection with 2013 Direct Placement (net of issuance costs), Amount	2,573	4	2,569
Issuance of shares of common stock and warrants in connection with 2013 Direct Placement (net of issuance costs), Shares		4,228,000
Warrants issued in connection with loans payable	652,000		652,000
Share-based compensation expense	1,301	1	1,300
Share-based compensation expense, Shares		237,000
Net loss	(25,948)			(25,948)
Ending Balance at Dec. 31, 2013	$ 8,296	$ 48	$ 176,396	$ (168,148)
Ending Balance, Shares at Dec. 31, 2013	47,501,596	47,502,000

Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	$ (25,948)	$ (22,673)
Adjustments to reconcile net loss:
Write-off of unamortized loan costs	983
Depreciation and amortization	2,439	970
Impairment of long-lived assets	1,011
Bad debt expense	46
Write-off of unamortized financing costs	41	62
Stock-based compensation	1,301	1,488
Amortization of deferred financing costs	250
Change in fair value of warrant liability	296
Inventory reserve	325	0
Changes in operating assets and liabilities:
Accounts receivable	77	(180)
Inventory	121	(676)
Prepaid expenses and other current assets	86	96
Other assets	36	(20)
Accounts payable and accrued expenses	(484)	1,390
Other current liabilities	27	10
Deferred rent	(24)	6
Deferred revenue	4	303
Net cash used in operating activities	(19,413)	(19,224)
Cash flows from investing activities:
Purchases of property and equipment	(5,188)	(6,158)
Net cash used in investing activities	(5,188)	(6,158)
Cash flows from financing activities:
Net proceeds from private placements/public offerings	21,174	5,202
Net proceeds from long term debt	5,755
Repayment of long term debt	(6,425)
Proceeds from exercise of stock options	18	45
Net cash provided by financing activities	20,522	5,247
Net decrease in cash and cash equivalents	(4,079)	(20,135)
Cash and cash equivalents at beginning of period	7,862	27,997
Cash and cash equivalents at end of period	3,783	7,862
Supplemental Schedule of Noncash Investing and Financing Activities:
Non-cash interest expense		41
Reclassification of MelaFind® components from other assets to property and equipment		522
Reclassification of warrant liability to stockholders equity	652
Reclassification of MelaFind® components from property and equipment to inventory	$ 5,402

Company

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Company

1. Company

MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company focused on the commercialization of our flagship product, MelaFind ^® , the further design and development of MelaFind ^® and our technology. MelaFind ^® is a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of melanoma. MelaFind ^® features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that were ‘trained’ on our proprietary database of melanomas and benign lesions. This then provides information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion.

The components of the MelaFind^® system include:

•

a hand-held component, which employs high precision optics and multi-spectral illumination (multiple colors of light including near infra-red);

•

a proprietary database of pigmented skin lesions, believed to be the largest positive prospective database to date in the U.S.; and

•

lesion classifiers, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.

In November 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) for the MelaFind ^® Pre-Market Approval (“PMA”) application and in September 2011 received Conformite Europeenne (“CE”) Mark approval for MelaFind ^®. On March 7, 2012, the Company installed the first commercial MelaFind ^® systems, and proceeded with the commercial launch of MelaFind ^®. We are currently conducting a Post-Approval Study (“PAS”) evaluating the sensitivity and false positive rate of physicians after using MelaFind^®.

In 2012 the Company evolved from a research and development company to a commercial enterprise. The launch of MelaFind^® in 2012, and the subsequent commercialization activities following the launch did not meet the Company’s initial goals and objectives. Revenues were lower than forecasted and expenses continued to increase throughout 2012 and into 2013. Our cash used in operating activities for the year ended December 31, 2013 and December 31, 2012 totaled $19,413 and $19,224, respectively, and net revenues totaled $536 and $278, respectively.

In mid 2013, a significant cost reduction program was put into place (see Note 16). On November 11, 2013, a new CEO was brought on board and a newly refocused “Go-to-Market” strategy focusing on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma was adopted. As part of this strategy, in late December, we elected to change our business model from a rental to a sale model for the MelaFind^® device. The Company has reduced its costs, brought new and experienced talent to its management team and has reconsidered the approach to the commercialization of the MelaFind^® device. The Company has also begun the process of obtaining a coverage determination from the Centers for Medicare & Medicaid Services, the federal agency that administers Medicare, in order to obtain reimbursement by Medicare for use of the MelaFind^® device. The Company anticipates that this process could take up to two years. Once a coverage determination has been made, the Company plans to seek reimbursement by Medicaid, Medicare and other third-party payers.

On August 22, 2013, the Company received a notice from The NASDAQ Stock Market that, for the previous 30 consecutive business days, the Company was not in compliance with a Nasdaq rule for continued listing that requires a listed company’s common stock to maintain a minimum bid price of $1.00 per share. The Company was granted an automatic 180 grace period by NASDAQ in which to regain compliance. On February 19, 2014, we were notified by NASDAQ that the Company was eligible for an additional 180 day grace period and has until August 18, 2014 to regain compliance with NASDAQ’s minimum bid price requirement.

On October 17, 2013, the FDA sent the Company a letter stating the information in the August 8, 2013 progress report with respect to the PAS was inadequate to allow the agency to complete its review and therefore the FDA asked for additional information. Because of rate of accrual issues, the FDA’s letter informed the Company that its study status was revised on the FDA’s website to “Progress Inadequate.” On September 9, 2013, the Company placed this study on hold to investigate enrollment. On November 15, 2013, the Company responded to the FDA’s letter, outlining an enrollment plan as well as a new enrollment schedule. On January 2, 2014, the FDA prompted an interactive review process to obtain further additional information regarding the Company’s response. On January 13, 2014, the Company’s enrollment plan and enrollment schedule was approved by the FDA and the interactive review process was closed as the FDA deemed the Company has sufficiently met the reporting expectations of the report. The Company’s new study timeline was approved for study restart in January 2014, steps to restart the study have been initiated. The FDA noted in their January 13, 2014 email that the status would remain as “Progress Inadequate” and that the status would be reassessed upon review of the next interim report date, February 8, 2014, based on the newly approved January 2014 restart timeline. As of the Company’s February 24, 2014 teleconference with the FDA, they noted that they have not had time to read our February 8, 2014 report and therefore the status has not been reviewed.

Basis of Presentation	12 Months Ended
Basis of Presentation	Dec. 31, 2013
Accounting Policies [Abstract]
Basis of Presentation	2. Basis of Presentation The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Liquidity and Going Concern The Company has experienced recurring losses and negative cash flow from operations and management expects these conditions to continue for the foreseeable future. As the result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. Management recently put in place a cost reduction program that included staff reductions, the elimination or deferral of all nonessential projects and activities and the scaling back or discontinuance of general corporate activities (referred to as “Cost Reduction Plan”) to preserve liquidity. In addition, as discussed below, in October 2013 the Company raised net proceeds of approximately $5,500 from the sale of common stock and warrants to strengthen the Company’s financial position, and in February 2014 the Company raised net proceeds of approximately $11,500 from the sale of convertible preferred stock, common stock and warrants (see Note 17). The Company continues to incur net losses. These net losses and the $6,400 payment to Hercules made in September have had a significant negative impact on the Company’s working capital and financial position and may impact its future ability to meet its obligations in the ordinary course of business. As a result, management believes that, even with cash and cash equivalents held at December 31, 2013, together with the net proceeds from the February 2014 financing and estimated revenue, there is significant doubt about our ability to continue as a going concern. The Company continues to assess the effects of its previously announced Cost Reduction Plan and is prepared to reduce various operational costs. Although the Company has no specific arrangements or plans, the Company will need additional capital during the next 12 months, which may take the form of equity or debt, on either a loan or convertible basis. However, under the terms of the securities purchase agreement entered into in connection with its February 2014 financing, the Company is prohibited from issuing (or entering into any agreement to issue) any equity securities in connection with a financing until the later of July 31, 2014 or 2 months after the effectiveness of the re-sale registration statement the Company is required to file in connection with that financing. The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America (GAAP) applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. In addition, as of December 31, 2013, the Company had an accumulated deficit of $168,148, had incurred a net loss for the year ended December 31, 2013 of $25,948 and had positive working capital of $4,699. Funding has been provided by related parties as well as new investors committed to make it possible to maintain, expand, and ensure the advancement of the MelaFind^® product. The Company expects expenses will increase in connection with its continued commercialization and development activities related to MelaFind^®. Having commenced commercialization in March 2012, the Company expects to incur additional medical, marketing and sales expenses in the near future and to incur additional contract manufacturing and inventory expenses in the future which will require additional funding. Furthermore, having recently commenced a refocused marketing strategy focusing on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma, the Company expects to incur additional expenses continuing to transition its operations and implement its new refocused marketing strategy. As a result, the Company expects to continue to incur significant and increasing operating losses for the foreseeable future and cannot determine at this time when it will generate any significant revenues. As of December 31, 2013, the Company’s total of cash and cash equivalents was approximately $3,783. Subsequent to year end, the Company raised approximately $12,300 in gross proceeds from a private placement of the Company’s convertible preferred stock and warrants to purchase shares of its common stock. In the first quarter of 2014, the Company paid a total of $2,460, and may be required to pay an additional $1,476, in liquidated damages to the investors in this private placement as a result of its failure to file and have declared effective a registration statement in accordance with the time periods set forth in a registration rights agreement between the Company and the investors. Should the Company experience unforeseen expenses, or if anticipated revenues are not realized, the effect could have a further negative impact on management’s estimated operating results over the next twelve months. If existing cash is insufficient to satisfy the Company’s liquidity requirements, or if it develops additional products, the Company may seek to sell additional equity or debt securities or obtain a credit facility, which will be even more difficult due to the current tightness in the credit markets. If additional funds are raised through the issuance of debt securities, these securities would have rights senior to those associated with the Company’s common stock and could contain covenants that would restrict the Company’s operations. Any additional financing may not be available in amounts or on terms acceptable to the Company, or at all. If the Company is unable to obtain any additional financing, it may be required to reduce the scope of, delay or eliminate some or all of planned product research development and commercialization activities, which could harm its business.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

Concentration of Credit Risk

The Company performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for uncollectible accounts receivable based upon the expected collectability of all accounts receivable.

Cash and cash equivalents

Cash equivalents primarily represent funds invested in money market funds, bank certificates of deposit and U.S. government debt securities with an original maturity of three months or less at the date of acquisition.

At year end, the Company has maintained bank balances in excess of insurance limits established by the Federal Deposit Insurance Corporation. The Company has not experienced any losses with respect to cash. Management believes the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could materially differ from those estimates.

Allowance for Doubtful Accounts

The Company establishes an allowance for uncollectible trade accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability of outstanding balances. These provisions are established when the aging of outstanding amounts exceeds allowable terms and are re-evaluated at each quarter end for adequacy. In determining the adequacy of the provision, the Company considers known uncollectible or at risk receivables.

Inventories

Inventories consist of finished products that are stated at the lower of cost (first-in, first-out) or market value. As of December 31, 2013 the reserve for obsolete inventory totaled $325. The Company reserved for specific inventory items that are no longer being used in the devices.

In mid 2013, a significant cost reduction program was put into place. On November 11, 2013, a new CEO was brought on board and a newly refocused “Go-to-Market” strategy focusing on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma was adopted. As part of this strategy, in late December, we elected to change our business model from a rental to a sale model for the MelaFind^® device. In accordance with this new sales model, the Company has reclassed approximately $5,402 of MelaFind^® devices from property and equipment into inventory.

Business Segments

The Company’s operations are confined to one business segment: the design, development and commercialization of MelaFind^®.

Revenue recognition

The Company considers revenue to be earned when all of the following criteria are met: persuasive evidence a sales arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. The Company’s agreements with dermatologists regarding the MelaFind ^® system combine the elements noted above with a future service obligation. While the Company was required to place the MelaFind ^® systems with dermatologists for their exclusive use, under the Company’s previous rental model with respect to MelaFind^® placements, ownership of the MelaFind ^® systems remains with the Company. In December 2013, the Company changed its business model from a rental and usage model, to a sales model for our MelaFind ^® product. Therefore, the Company will recognize revenues for product sales when title and risk of loss transfers to customers, which is after installation and training on the MelaFind^® system, and when reliable estimates of sales allowances and warranties can be made and collectability is reasonably assured. The Company will regularly review the information related to these estimates and adjust the reserves accordingly.

During 2013, the Company generated revenue from either usage based on the number of patient sessions, or lesions examined, or a fixed monthly fee. Electronic record cards activate the MelaFind ^® system, capture data and store the data initial installation fee for each MelaFind ^® system which covers training, delivery, initial supplies, maintenance and the right to use MelaFind^®. In accordance with the accounting guidance regarding multiple-element arrangements, the Company allocates total contract consideration to each element based upon the relative standalone selling prices of each element, and recognizes the associated revenue for each element as delivery occurs or over the related service period, generally expected to be two years. Revenues associated with undelivered elements are deferred until delivery occurs or services are rendered. The significant judgments we make relate to allocation of the contract consideration to each element whereby changes in standalone selling price could impact the amount of revenue recognized in a specific period and estimates of uncollectible accounts receivables.

In Germany, the typical contract with dermatologists calls for an installation or fixed monthly fee. Additionally, the Company typically charges a per patient usage charge. Revenue generated from German contracts is recognized when earned.

Cost of Revenue

Costs of revenue are associated with: the placement of the MelaFind^® system in the doctor’s office, the cost of consumables delivered at installation, the cost of the electronic record cards, technical support costs and depreciation expense of the MelaFind ^® system placed with the customer which, under the Company’s previous rental model with respect to MelaFind^® placements, remains the property of the Company. Certain product quality and manufacturing overhead costs associated with supporting the contract manufacturers of MelaFind ^® are allocated to costs of revenue.

Property and Equipment

For the year ended December 31, 2013 and 2012, the Company capitalized approximately $5,188 and $6,158, respectively of MelaFind ^® system costs. Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the related assets (generally three to five years). Costs incurred for maintenance and repairs are expensed as incurred and expenditures for major replacements and improvements are capitalized and depreciated over their estimated remaining useful lives. Depreciation expense for the years ended December 31, 2013 and 2012 was $2,434 and $957, respectively.

Patents and Trademarks, Net

The Company capitalizes the costs of obtaining its patents and registration of Trademarks. Such costs are accumulated and capitalized during the filing periods, which can take several years to complete. Successful applications that result in the granting of a patent or trademark are then amortized over 15 years on a straight-line basis. Unsuccessful applications are written off and expensed in the fiscal period where the application is abandoned or discontinued.

Deferred Financing Costs

Financing costs incurred in connection with the Hercules Technology Growth Capital, Inc. (“Hercules”) note payable were deferred and are being amortized over the term of the note using the effective interest rate method. These financing costs were written off when the loan was repaid in September 2013. As of December 31, 2013 and 2012 the Company recorded deferred financing costs of $0 and $106, respectively, in other assets in the accompanying balance sheets.

Deferred Revenue and Prepaid Expenses

Deferred placement revenue relates primarily to rental placement fees and product sales or services paid but not delivered at period end. The Company has certain customer arrangements providing for multiple years content services. To the extent deferred services are to be provided beyond twelve months they are treated as long-term. Prepaid expenses are recorded at amounts paid to suppliers or others. Amounts recorded are evaluated for impairment each reporting period.

Long-lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered to be impaired when the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition exceeds its carrying amount. The amount of impairment loss, if any, is measured as the difference between the net book value of the asset and its estimated fair value. (See Note 5)

Research and Development

Expenditures for research and development are expensed as incurred.

Accrued Expenses

As part of the process of preparing financial statements, we are required to estimate accrued expenses. This process involves identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for such service where we have not been invoiced or otherwise notified of the actual cost. Examples of estimated accrued expenses include:

•

professional service fees;

•

contract clinical and regulatory related service fees;

•

fees paid to contract manufacturers in conjunction with the production of MelaFind^® components or materials; and

•

fees paid to third party data collection organizations and investigators in conjunction with the clinical trials and FDA and other regulatory review.

In connection with such service fees, our estimates are most affected by our projections of the timing of services provided relative to the actual level of services provided by such service providers. The majority of our service providers invoice us monthly in arrears for services performed. In the event that we do not identify certain costs that have begun to be incurred or we under or overestimate the level of services performed or the costs of such services, our actual expenses could differ from such estimates. The date on which certain services commence, the level of services performed on or before a given date, and the cost of such services are often subjective determinations. We make these judgments based upon the facts and circumstances known to us and accrue for such costs in accordance with accounting principles generally accepted in the U.S. This is done as of each balance sheet date in our financial statements.

Deferred Rent

Operating lease agreements which contain provisions for future rent increases or periods in which rent payments are reduced or abated are recorded in monthly rent expense in the amount of the total payments over the lease term divided by the number of months of the lease term. The difference between rent expense recorded and the amount paid is credited or charged to deferred rent which is reflected on the accompanying balance sheet.

Stock-Based Compensation

We record compensation expense associated with stock options, restricted stock awards and other forms of equity compensation in accordance with FASB ASC 718, Compensation-Stock Compensation. The fair value of an equity award is determined at the date of grant using the Black-Scholes Model and the fair value of the equity award is expensed over the service period. The most significant inputs used to value an equity award include current stock price, the amount the employee must pay to acquire the equity award, volatility rate, interest rate and estimated term. For equity awards that vest upon achieving a defined milestone, the underlying compensation charge is recorded, when it is probable that the milestone will be achieved. It is then amortized over the estimated period to satisfy vesting requirements. The probability of vesting is updated at each reporting period and compensation is adjusted accordingly. The significant judgments relate to the assumptions used in the valuation model to determine the fair value of the equity instrument including the volatility rate, term and interest rate. Any increases (decreases) in either of the volatility rate, the term or the interest rate would increase (decrease) the value of the equity instrument and the corresponding compensation expense recognized each period. Estimates of performance based awards vesting can also have a significant impact on recognized stock compensation as the likelihood of a performance based award vesting can change from period-to-period with changes in estimates included in current period operations.

Stock-based compensation to non-employee consultants is granted for services rendered and is completely vested on the grant date. The fair value of the award is determined on the date of grant using the Black-Sholes Model and the fair value is expensed in current period operations.

Income Tax Expense Estimates and Policies

The Company accounts for income taxes using the asset and liability method for deferred income taxes.

The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that a tax benefit will not be realized.

With respect to uncertain tax positions, the Company would recognize the tax benefit from an uncertain tax position only if it is more-likely-than-not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position. The tax benefits to be recognized in the financial statements from such a position would be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. The Company currently has no uncertain tax positions.

The Company does not have any unrecognized tax benefits which would favorably affect the effective tax rate if recognized in future periods, or accrued penalties and interest. If such matters were to arise, the Company would recognize interest and penalties related to income tax matters in income tax expense. The earliest open tax year subject to examination is 2009.

Net Loss Per Common Share

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents outstanding as of December 31, 2013 and 2012 consist of stock options, warrants and restricted stock awards which are summarized as follows:


	Year Ended December 31,
	2013		2012
Common stock options		3,065,714		2,426,533
Warrants		12,093,591		200,000
Restricted Stock Awards		99,375		—

Total		15,258,680		2,626,533

Comprehensive loss

For all periods presented, the Company had no comprehensive income items and accordingly there is no difference between the reported net loss and per share amounts per the Statements of Operations and comprehensive net loss and related per share amounts.

Litigation

From time to time, the Company may become involved in litigation and other legal actions. The Company estimates the range of liability related to any pending litigation where the amount and range of loss can be estimated. The Company records its best estimate of a loss when the loss is considered probable. Where a liability is probable and there is a range of estimated loss with no best estimate in the range, the Company records a charge equal to at least the minimum estimated liability for a loss contingency when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and (ii) the range of loss can be reasonably estimated. Through the date of these financial statements, the Company is currently not involved in litigation or other legal actions.

Fair Value Measurements

The Company has adopted the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” as of January 1, 2008 for financial instruments. This standard defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820 permits an entity to measure certain financial assets and financial liabilities at fair value with changes in fair value recognized in earnings each period.

Warrant Liability

The Company accounts for the 6,857,142 common stock warrants issued in connection with the October 31, 2013 financing in accordance with the guidance contained in ASC 815-40-15-7D, “Contracts in Entity’s Own Equity” whereby under that provision they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of warrants issued by the Company in connection the transaction has been estimated using a Black-Scholes valuation.

Recently Issued Accounting Standards

The Financial Accounting Standards Board (“FASB”) periodically issues new accounting standards in a continuing effort to improve standards of financial accounting and reporting. We have reviewed the recently issued pronouncements and concluded that there are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on the Company’s financial position, results of operations or cash flows.

Management’s Evaluation of Subsequent Events

Management evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, management did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements (See Note 17).

Foreign Exchange

The Company’s operations in Germany use the U.S. dollar as its functional currency and from time to time conducts business in Euros. For all periods presented, aggregate foreign exchange transaction gains and losses were not material.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

Inventory

12 Months Ended

Dec. 31, 2013

Inventory Disclosure [Abstract]

Inventory

4. Inventory

Inventory consists of the following:


	December 31,
	2013			2012
MelaFind^® Systems	$	5,402		$	—
Mela record cards		328			333
Accessories		226			343

		5,956			676
Reserve for obsolete inventory		(325	)		—

	$	5,631		$	676

At December 31, 2013, under the Company’s new sales model, approximately $5,402 of MelaFind ^® systems have been reclassified from property and equipment into inventory.

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

Property and Equipment

12 Months Ended

Dec. 31, 2013

Property Plant And Equipment [Abstract]

Property and Equipment

5. Property and Equipment

Property and equipment, at cost, consists of the following:


	December 31,						Estimated
	2013			2012			Useful Life		Useful Life
Leasehold improvements	$	906		$	906			Lease Term		Lease Term
Laboratory and research equipment		1,084			1,084			3-5 years		3-5 years
Office furniture and equipment		2,023			2,023			3-5 years		3-5 years
MelaFind^® Systems		5,081			6,306			3 years		3 years

		9,094			10,319
Accumulated depreciation and amortization		(5,403	)		(2,969	)

	$	3,691		$	7,350

Depreciation expense amounted to approximately $2,434 and $957 for the years ended December 31, 2013 and 2012, respectively.

For the year ended December 31, 2013, the Company’s marketing shifted focus to large cancer centers and high risk patients, and the Company took an impairment charge of approximately $1,011 against its MelaFind ^® systems previously placed in locations that do not fit this profile. However, as these user agreements expire over the next 2 years, we anticipate that the affected systems will be redeployed in some capacity. Under the Company’s new sales model, approximately $5,402 has been reclassified into inventory.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

Patents and trademarks	12 Months Ended
Patents and trademarks	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
Patents and trademarks	6. Patents and trademarks Patents and trademarks as shown in the accompanying balance sheets are net of accumulated amortization of $232 and $227 at December 31, 2013 and 2012, respectively. Amortization expense related to all patents was approximately $5 and $12 for the years ended December 31, 2013 and 2012, respectively. Amortization expense of currently held patents is expected to amount to $5 for each of the years ending December 31, 2014 through 2018, respectively.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2013

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

7. Commitments and Contingencies

The Company is obligated under a non-cancelable operating lease for office, lab, and manufacturing space expiring December 2016. The lease is subject to escalations for increases in operating expenses. For the years ended December 31, the approximate aggregate minimum future payments due under this lease are as follows:


2014	$	478
2015		478
2016		477

TOTAL	$	1,433

Rent expense charged to operations amounted to approximately $509 and $483 for the years ended December 31, 2013 and 2012, respectively.

From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material in which case we will make separate disclosure as required.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Debt	12 Months Ended
Debt	Dec. 31, 2013
Debt Disclosure [Abstract]
Debt	9. Debt On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc., a venture capital lender, whereby the Company borrowed $6,000 (“Loan”). The Loan accrued interest at a rate of 10.45%. The term of the Loan was 42 months with interest payments only during the first 12 months. On September 10, 2013, the Company elected to prepay the Loan and paid Hercules approximately $6,400, including the end of term fee of $425, to settle all obligations to Hercules. Hercules agreed to waive the prepayment penalty that was defined in the loan documents. Upon executing the loan documents on March 15, 2013 the Company became obligated to issue to the Lender a warrant to purchase shares of the Company’s common stock upon approval by the Company’s stockholders of a proposal to increase the Company’s number of authorized shares of common stock at its 2013 Annual Meeting of Stockholders. The number of shares that could be acquired upon exercise of the warrant and the exercise price per share, were not fixed on March 15, 2013 but would be determined when the warrant was issued based on a defined formula using trading prices of the Company’s common stock during certain periods prior to the issuance of the warrant. The Company’s stockholders approved the increase in the number of authorized shares of common stock on April 25, 2013 and on April 26, 2013 the warrant was issued to the Lender. The terms of the warrant were fixed on the date of issuance whereby the Lender received a warrant to purchase 693,202 shares of common stock at an exercise price of approximately $1.12 per share (“Warrant”). The Warrant expires on April 26, 2018. For financial reporting purposes, the $6,000 funded by the Lender on March 15, 2013 was allocated first to the fair value of our obligation to issue the warrant (“Warrant Obligation”) that totaled approximately $563 and the balance was reduced further by the Lender’s costs and fees (“Costs”), resulting in an initial carrying value of the loan of approximately $5,300. The Company used a Level 3 fair value measurement to determine fair value of the Warrant Obligation, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. During the period from the loan inception date until the Warrant Obligation was fulfilled and the Warrant was issued, the Warrant Obligation was reflected as a long-term liability at fair value. Changes in the fair value (“mark-to-market adjustments”) of the Warrant Obligation of approximately $90 are included in operating results. The fair value of the Warrant Obligation was determined using the Monte Carlo pricing model that used various assumptions that included: stock prices ranging from $1.16 to $1.18 per share, volatility of 77%, time to maturity of 5 years, exercise prices ranging from $1.15 to $1.16 and a risk free interest rate of return of .84%. Due to the nature of the Monte Carlo model, a 10% change in the underlying unobservable inputs would not have a significant impact on the fair value. The value of the Warrant Obligation combined with the Costs resulted in an initial loan discount of approximately $727. The terms of the Loan required us to pay the Lender a fee of $425 at the maturity of the Loan (referred to as “Fee”). The loan discount and the Fee were being amortized as additional interest expense over the life of the loan using the interest method. As discussed above, prior to the terms of the warrant being fixed on April 26, 2013, the Warrant Obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the Warrant Obligation was accounted for as a derivative reflected as a long-term liability until the Warrant was issued on April 26, 2013. The terms of the Warrant upon issuance no longer required derivative accounting under ASC 815 and therefore the fair value of the Warrant was classified within stockholders equity. As the result of us electing to prepay the loan on September 10, 2013, the unamortized loan discount, fee and deferred financing costs that were expensed were approximately $983.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

Recurring Fair Value Measurements

12 Months Ended

Dec. 31, 2013

Fair Value Disclosures [Abstract]

Recurring Fair Value Measurements

10. Recurring Fair Value Measurements

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows:

•

Level 1: Observable inputs such as quoted prices in active markets;

•

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

•

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company’s financial instruments are cash and cash equivalents, accounts payable, and derivative warrant liabilities. The recorded values of cash equivalents and accounts payable approximate their fair values based on their short-term nature. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of our warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures.

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2013 and October 31, 2013 is as follows:


Black-Scholes Warrant Pricing	October 31, 2013			December 31, 2013
Stock Price	$	0.85		$	0.85
Risk-free Rate (5-year U.S. Treasury Yield)		1.31	%		1.75	%
Volatility (Annual)		94.78	%		93.43	%
Time to Maturity (Years)		5.50			5.33

At December 31, 2013 and December 31, 2012, the estimated fair values of the liabilities measured on a recurring basis are as follows:


	Fair Value Measurements at December 31, 2013
	Balance at December 31, 2013		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Warrant derivative liabilities	$	3,017	$	—	$	—	$	3,017

Total	$	3,017	$	—	$	—	$	3,017

Fair Value Measurements at December 31, 2012

Balance at
December 31, 2012

Quoted Prices in
Active Markets
(Level 1)

Significant Other
Observable Inputs
(Level 2)

Significant
Unobservable Inputs
(Level 3)

Warrant derivative liabilities

—

Total

—

The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the years ended December 31, 2013 and 2012:


	Fair Value
	Measurements Using
	Significant
	Unobservable Inputs
	(Level 3)
	Warrant Derivative
	Liabilities
Beginning Balance at January 1, 2013	$	—
Issuance of warrants with derivative liabilities		3,373
Changes in estimated fair value		296
Reclassification of derivative liability to additional paid-in capital		(652	)

Ending balance at December 31, 2013	$	3,017

Reclassification of derivative liability to additional paid-in capital relates to the warrants issued in connection with the debt financing that occurred on March 15, 2013. These warrants were accounted for as a liability until such time as the stockholders of the Company approved an increase in the number of authorized shares of the Company’s common stock.

Stockholders' Equity

12 Months Ended

Dec. 31, 2013

Equity [Abstract]

Stockholders' Equity

11. Stockholders’ Equity

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company’s board of directors. As of December 31, 2013, there are no shares of preferred stock issued or outstanding.

On February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, with certain funds managed by Sabby Management, LLC and Broadfin Capital, LLC (together, the “Purchasers”), the Company sold (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, par value $0.10 and a stated value of $1,000 per share (the “Series A Preferred Stock”), convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of common stock for aggregate gross proceeds of $12,300. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. The number of shares issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar transactions. In connection with the financing, Broadfin Capital, LLC has been granted the right to designate one director to our Board of Directors, so as long as it retains 30% of its investment in the Series A Preferred Stock (or the shares of common stock underlying the Series A Preferred Stock) or holds any warrants, and the Purchasers have been granted rights of participation in future offerings of our securities for one year. As a condition of the financing, our directors, pursuant to subscription agreements dated as of January 31, 2014, purchased an aggregate of 202,703 shares of common stock, at a price of $0.74 per share, for aggregate gross proceeds of $150,000 (See Note 17).

Common Stock

The Company is authorized to issue 95,000,000 shares of Common Stock with a par value of $0.001 per share.

In June 2012, the Company entered into a sales agreement with Cowen and Company, LLC, to sell shares of the Company’s common stock through an “at-the-market” equity offering program (the “ATM Program”), which was terminated on February 15, 2013. During the year ended December 31, 2013, the Company sold approximately 4.7 million shares under the ATM Program for gross and net proceeds of approximately $8,800 and $8,500, respectively. During the term of the ATM Program, the Company sold a total of approximately 6.6 million shares for aggregate gross and net proceeds of approximately $14,400 and $13,800, respectively.

On February 12, 2013 the Company entered into an underwriting agreement with Cowen and Company, LLC, relating to the public offering of 6.1 million shares of the Company’s common stock, at a price to the public of $1.30 per share less underwriting discounts and commissions. The gross proceeds to the Company from the sale of the Common Stock totaled $7,900. After deducting the Underwriters’ discounts and commissions and other estimated offering expenses payable by the Company, net proceeds were approximately $7,300. The offering closed on February 15, 2013. The Common Stock was offered and sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the Securities and Exchange Commission (the “SEC”) on February 11, 2013, in connection with a takedown from the Company’s effective shelf registration statement on Form S-3 (File No. 333-167113) declared effective by the SEC on June 1, 2010.

Warrants

On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc. In connection with the Loan, Hercules, as additional consideration, received a five year warrant to purchase 693,202 shares of common stock at an exercise price of approximately $1.12 per share.

October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6,000 registered offering of 4,228,181 shares of the Company’s common stock, fully paid prefunded warrants (“Series B Warrants”) to purchase up to 4,343,247 shares of its common stock and additional warrants (“Series A Warrants”) to purchase up to 6,857,142 shares of its common stock. The Series A Warrants are exercisable beginning on May 1, 2014 at a price of $0.85 per share and expire on May 1, 2019. The Series B Warrants are exercisable immediately for no additional consideration. The offering closed on October 31, 2013.

The Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge in the Statements of Operations. The change in fair value of the warrant liability for the year ended December 31, 2013, was $296, which includes a change in fair value from the Series A warrants of $205.

As of December 31, 2013, the Company had the following warrants issued:


		Total
Issue Date	Holder	Warrants		Ex. Price
5/7/2009	Kingsbridge Capital Limited		200,000	$	11.35
4/26/2013	Hercules Technology Growth Capital		693,202	$	1.12
10/31/2013	Sabby Management, LLC “Series A”		6,857,142	$	0.85
10/31/2013	Sabby Management, LLC “Series B Prefunded Warrants”		4,343,247	$	0.70

			12,093,591

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Stock-Based Compensation

12 Months Ended

Dec. 31, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

12. Stock-Based Compensation

Stock Options

On April 25, 2013, at the Company’s 2013 Annual Meeting of Stockholders, the Company’s stockholders approved the Company’s adoption of the new 2013 Stock Incentive Plan (“2013 Plan”) having terms substantially similar to the Company’s 2005 Stock Incentive Plan (the “2005 Plan”) and having 3,500 shares available for issuance in respect of awards made there under. As of December 31, 2013, the aggregate number of shares of common stock remaining available for issuance for awards under the 2013 Plan and the 2005 Plan totaled approximately 3,729,853.

Stock awards under the Company’s stock option plans have been granted with exercise prices which are no less than the market value of the stock on the date of the grant. Options granted under the 2013 and 2005 Plan are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant. The plans provide for the granting of a maximum number of shares of common stock of 7,224,028 of which 3,729,853 are available for future grant as of December 31, 2013. Compensation expense recognized in the Statement of Operations during 2013 and 2012 for stock options and restricted stock awards amounted to $1,301 and $1,488, respectively. Cash received from options exercised under all share-based payment arrangements for the years ended December 31, 2013 and 2012 was $18 and $45, respectively.

The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation and assumptions as noted in the following table:


	December 31, 2013			December 31, 2012
Expected life		5-10 years			5-10 years
Expected volatility		72-77	%		74-80	%
Risk-free interest rate		0.71-2.45	%		0.91-1.60	%
Dividend yield		—			—

The expected life of the options is based on the observed and expected time to full-vesting, forfeiture and exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. The expected volatility assumptions were determined based upon the historical volatility of the Company’s daily closing stock price. The risk-free interest rate is based on rates provided by the U.S. Treasury with a term equal to the expected life of the option. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

At December 31, 2013, stock options to purchase 3,065,714 shares of common stock at exercise prices ranging from $0.65 to $10.35 per share are outstanding and are exercisable at various dates through 2023. The total number of options exercisable at December 31, 2013 and 2012 was 1,261,355 and 1,620,320 respectively, with weighted average exercise prices of $2.56 and $3.99, respectively. The aggregate intrinsic value of the options exercisable at December 31, 2013 is $0.

The status of the Company’s stock option plans during the periods indicated is summarized as follows:


						Weighted
						Average
				Weighted		Remaining
				Average		Contractual		Aggregate
	Number of			Exercise		Term in		Insintric
	Shares			Price		Years		Value
Outstanding at December 31, 2011		2,057,104			4.35		6.6

Granted		863,202			3.35		9.5
Exercised		(61,796	)		2.91
Forfeited or expired		(431,977	)		4.44

Outstanding at December 31, 2012		2,426,533			4.01		7.0	$	29

Granted		4,994,465			1.46		9.5
Exercised		(18,059	)		1.00				17
Forfeited or expired		(4,337,225	)		2.77				27

Outstanding at December 31, 2013		3,065,714			1.62		9.0

Vested and exercisable at December 31, 2013		1,261,355		$	2.56		8.1	$	—

During the years ended December 31, 2013 and 2012 the weighted average fair value of options granted, estimated as of the grant date using the Black-Scholes option valuation model, was $0.60 and $2.28 per share, respectively. The total intrinsic value of options exercised during the years ended December 31, 2013 and 2012 was $17 and $86, respectively. The requisite service periods for options granted during 2013 and 2012 for employees was four years and for directors was one year.

The following table summarizes information about stock options outstanding at December 31, 2013:


	Options Outstanding						Options Exercisable
			Weighted-
			Average		Weighted-				Weighted-
			Remaining		Average				Average
	Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life		Price		Exercisable		Price
$0.65-$3.00		2,412,651		9.65 years	$	0.89		694,742	$	1.17
$3.01-$6.00		500,513		7.72 years		3.40		441,038		3.38
$6.01-$10.35		152,550		3.35 years		7.28		125,575		7.38

$0.65-$10.35		3,065,714		9.02 years	$	1.62		1,261,355	$	2.56

As of December 31, 2013, of the total 3,065,714 options outstanding, 1,804,359 have not vested. Of this total unvested amount, 650,850 will vest upon the attainment of certain milestones, and the balance will vest over the requisite service period. There was $755 of total unrecognized compensation cost related to unvested options, of which approximately $308 will be recognized upon achievement of performance milestones and $447 upon completion of the requisite service period. On February 11, 2013, the Company’s former chief executive officer contractually agreed to not exercise 900,000 fully vested options until such time as the stockholders of the Company approve an increase in the number of authorized shares of the Company’s common stock, or, if earlier, the Company’s written consent. On April 25, 2013, the Company’s stockholders approved an increase in the authorized shares of common stock and therefore the restriction placed on the former CEO’s ability to exercise the 900,000 fully vested options lapsed. For financial reporting purposes, the Forbearance Agreement was accounted for at the time it was executed as a cancellation with no concurrent grant and therefore upon the lapsing of the exercise restriction on April 25, 2013, the Company recognized additional stock compensation of approximately $423.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Other Income	12 Months Ended
Other Income	Dec. 31, 2013
Other Income And Expenses [Abstract]
Other Income	13. Other Income In 2005, the Company discontinued all operations associated with its DIFOTI product. Under an exclusive sale and licensing agreement with KaVo Dental GmbH (“KaVo”) to further develop and commercialize DIFOTI, KaVo pays the Company an annual royalty based on the number of DIFOTI related systems sold per calendar year. Other income includes approximately $20 in royalty income in each of the years in the two year period ended December 31, 2013.

Related Party Agreements	12 Months Ended
Related Party Agreements	Dec. 31, 2013
Related Party Transactions [Abstract]
Related Party Agreements	14. Related Party Agreements *Consulting Agreement with Gerald Wagner, Ph.D.* In January 2007, Dr. Wagner, a former Director on the Company’s Board of Directors, entered into an amended and restated consulting contract with the Company. Under the terms of the amended contract, Dr. Wagner was paid a monthly retainer of $2.5 and was paid $2.5 for each additional consulting day. This amended agreement ended at the option of Dr. Wagner or the Company at any time, by providing fifteen days prior written notice, or immediately upon the mutual agreement of the Company and Dr. Wagner. The amounts paid to Dr. Wagner amounted to $0 and $30 in 2013 and 2012. Dr. Wagner resigned from the Company’s Board of Directors in December 2011 with the consulting contract remaining in effect until termination on December 31, 2012. *Transition Services Provided by Robert Coradini* On March 11, 2014, the Company agreed to pay Robert Coradini, a director and the Company’s former Interim Chief Executive Officer, approximately $48 in consideration for services provided in connection with the transition to a new Chief Executive Officer during the fourth quarter of 2013.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

Income Taxes

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

Income Taxes

15. Income Taxes

The Company accounts for income taxes using the asset and liability method for deferred income taxes.

The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.

The Company has incurred net losses since inception, accordingly, it has not provided for income taxes for the years ended December 31, 2013 and 2012.

The difference between the actual income tax benefit and that computed by applying the U.S. federal income tax rate of 34% to pretax loss from continuing operations is summarized below:


	For the years ended December 31,
	2013			2012
Computed expected tax benefit	$	(8,822	)	$	(7,709	)
State tax benefit, net of federal effect		(1,557	)		(1,360	)
Increase in the valuation allowance		10,379			9,069

Provision for income taxes	$	—		$	—

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2013 and 2012 are as follows:


	December 31,
	2013			2012
Deferred tax assets:
Net operating loss carryforward	$	35,086		$	26,471
Capitalized research and developmental costs		27,794			26,511
Non-cash compensation		3,681			3,200

Total deferred tax assets		66,561			56,182
Less valuation allowance		(66,561	)		(56,182	)

Net deferred tax assets	$	—		$	—

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based on the Company’s historical net losses, management does not believe that it is more-likely-than not that the Company will realize the benefits of these deferred tax assets and, accordingly, a full valuation allowance has been recorded against the deferred tax assets as of December 31, 2012 and 2013. The Company’s valuation allowance against its deferred tax assets increased by $10,379 and $9,069 for the years ended December 31, 2013 and 2012, respectively.

At December 31, 2013, the Company has net operating loss carryforwards of approximately $87,000 to offset future taxable income. The Company has experienced certain ownership changes which, under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, result in annual limitations on the Company’s ability to utilize its net operating losses in the future. The Company believes that these limitations may impact the Company’s ability to utilize its net operating losses in the future. The February 2014 equity raise by the Company, will likely limit the annual use of these net operating loss carryforwards.

FASB ASC 740 “Income Taxes” contains guidance with respect to uncertain tax positions which applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to recognize. Tax positions that meet the more likely than not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Restructuring Charge	12 Months Ended
Restructuring Charge	Dec. 31, 2013
Restructuring And Related Activities [Abstract]
Restructuring Charge	16. Restructuring Charge As discussed in Note 1, in response to recurring operating losses and limited liquidity, during August 2013 the Company’s Board of Directors approved the Cost Reduction Plan that included a reduction in work force and the prospective elimination or deferral of all nonessential projects and activities and the scaling back or discontinuance of general corporate activities. The communication to affected employees was made during August 2013. In connection therewith, the Company recorded a charge for employee termination benefits totaling approximately $100 that is reflected in the statement of operations as increases in cost of revenue, research and development and selling, general and administrative expenses of approximately $100, for the year ended December 31, 2013. As of December 31, 2013 substantially all termination benefits have been paid.

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2013
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events On February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, with certain funds managed by Sabby Management, LLC. and Broadfin Capital, LLC (together, the “Purchasers”), the Company sold (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, par value $0.10 and a stated value of $1,000 per share (the “Series A Preferred Stock”), convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of common stock for aggregate gross proceeds of $12,300. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. The number of shares issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar transactions. In connection with the financing, Broadfin Capital, LLC has been granted the right to designate one director to our Board of Directors, so as long as it retains 30% of its investment in the Series A Preferred Stock (or the shares of common stock underlying the Series A Preferred Stock) or holds any warrants, and the Purchasers have been granted rights of participation in future offerings of our securities for one year. As a condition of the financing, our directors, pursuant to subscription agreements dated as of January 31, 2014, purchased an aggregate of 202,703 shares of common stock, at a price of $0.74 per share, for aggregate gross proceeds of $150,000. In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. In addition to the registration rights, the Purchasers are entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, getting effective and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants, including the failure of the Company to file a resale registration statement by no later than February 25, 2014 and the failure of the Company to have such resale registration statement declared effective by the Securities and Exchange Commission (the “SEC”) by no later than March 7, 2014. The liquated damages will be payable upon the occurrence of each of those events and each monthly anniversary thereof until cured. The amount of liquated damages payable is equal to 10% of the aggregate purchase price paid by each Purchaser for the first two events (and/or the monthly anniversary of an event), 7.5% of the aggregate purchase price paid by each Purchaser for the third event (and/or the monthly anniversary of an event), 2.5% of the aggregate purchase price paid by each Purchaser for the fourth event (and/or the monthly anniversary of an event), and 1% of the aggregate purchase price paid by each Purchaser for the next two events (and/or the monthly anniversary of an event), in all up to a total of 32% of the aggregate purchase price paid by each Purchaser. The liquidated damages are prorated on a daily basis for each event until such event is cured. The terms of the Registration Rights Agreement required us to provide the Purchasers with a copy of the registration statement not less than 17 trading days prior to its filing with the SEC. The Company was unable to file the initial re-sale registration statement by February 25, 2014 or have it declared effective by March 7, 2014 and paid liquidated damages to the Purchasers in the aggregate amount of $2,460. On February 19, 2014, the Company was notified by NASDAQ that the Company was eligible for an additional 180 day grace period and has until August 18, 2014 to regain compliance with NASDAQ’s minimum bid price requirement.

Basis of Presentation (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Liquidity and Going Concern

Liquidity and Going Concern

The Company has experienced recurring losses and negative cash flow from operations and management expects these conditions to continue for the foreseeable future. As the result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. Management recently put in place a cost reduction program that included staff reductions, the elimination or deferral of all nonessential projects and activities and the scaling back or discontinuance of general corporate activities (referred to as “Cost Reduction Plan”) to preserve liquidity. In addition, as discussed below, in October 2013 the Company raised net proceeds of approximately $5,500 from the sale of common stock and warrants to strengthen the Company’s financial position, and in February 2014 the Company raised net proceeds of approximately $11,500 from the sale of convertible preferred stock, common stock and warrants (see Note 17).

The Company continues to incur net losses. These net losses and the $6,400 payment to Hercules made in September have had a significant negative impact on the Company’s working capital and financial position and may impact its future ability to meet its obligations in the ordinary course of business. As a result, management believes that, even with cash and cash equivalents held at December 31, 2013, together with the net proceeds from the February 2014 financing and estimated revenue, there is significant doubt about our ability to continue as a going concern. The Company continues to assess the effects of its previously announced Cost Reduction Plan and is prepared to reduce various operational costs. Although the Company has no specific arrangements or plans, the Company will need additional capital during the next 12 months, which may take the form of equity or debt, on either a loan or convertible basis. However, under the terms of the securities purchase agreement entered into in connection with its February 2014 financing, the Company is prohibited from issuing (or entering into any agreement to issue) any equity securities in connection with a financing until the later of July 31, 2014 or 2 months after the effectiveness of the re-sale registration statement the Company is required to file in connection with that financing.

The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America (GAAP) applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. In addition, as of December 31, 2013, the Company had an accumulated deficit of $168,148, had incurred a net loss for the year ended December 31, 2013 of $25,948 and had positive working capital of $4,699. Funding has been provided by related parties as well as new investors committed to make it possible to maintain, expand, and ensure the advancement of the MelaFind^® product.

The Company expects expenses will increase in connection with its continued commercialization and development activities related to MelaFind^®. Having commenced commercialization in March 2012, the Company expects to incur additional medical, marketing and sales expenses in the near future and to incur additional contract manufacturing and inventory expenses in the future which will require additional funding. Furthermore, having recently commenced a refocused marketing strategy focusing on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma, the Company expects to incur additional expenses continuing to transition its operations and implement its new refocused marketing strategy. As a result, the Company expects to continue to incur significant and increasing operating losses for the foreseeable future and cannot determine at this time when it will generate any significant revenues. As of December 31, 2013, the Company’s total of cash and cash equivalents was approximately $3,783. Subsequent to year end, the Company raised approximately $12,300 in gross proceeds from a private placement of the Company’s convertible preferred stock and warrants to purchase shares of its common stock. In the first quarter of 2014, the Company paid a total of $2,460, and may be required to pay an additional $1,476, in liquidated damages to the investors in this private placement as a result of its failure to file and have declared effective a registration statement in accordance with the time periods set forth in a registration rights agreement between the Company and the investors.

Should the Company experience unforeseen expenses, or if anticipated revenues are not realized, the effect could have a further negative impact on management’s estimated operating results over the next twelve months. If existing cash is insufficient to satisfy the Company’s liquidity requirements, or if it develops additional products, the Company may seek to sell additional equity or debt securities or obtain a credit facility, which will be even more difficult due to the current tightness in the credit markets. If additional funds are raised through the issuance of debt securities, these securities would have rights senior to those associated with the Company’s common stock and could contain covenants that would restrict the Company’s operations. Any additional financing may not be available in amounts or on terms acceptable to the Company, or at all. If the Company is unable to obtain any additional financing, it may be required to reduce the scope of, delay or eliminate some or all of planned product research development and commercialization activities, which could harm its business.

Concentration of Credit Risk

Concentration of Credit Risk

Cash and cash equivalents

Cash and cash equivalents

Use of Estimates

Use of Estimates

Allowance for Doubtful Accounts

Allowance for Doubtful Accounts

Inventories

Inventories

Business Segments

Business Segments

The Company’s operations are confined to one business segment: the design, development and commercialization of MelaFind^®.

Revenue recognition

Revenue recognition

Cost of Revenue

Cost of Revenue

Property and Equipment

Property and Equipment

Patents and Trademarks, Net

Patents and Trademarks, Net

Deferred Financing Costs

Deferred Financing Costs

Deferred Revenue and Prepaid Expenses

Deferred Revenue and Prepaid Expenses

Long-lived Assets

Long-lived Assets

Research and Development

Research and Development

Expenditures for research and development are expensed as incurred.

Accrued Expenses

Accrued Expenses

•

professional service fees;

•

contract clinical and regulatory related service fees;

•

fees paid to contract manufacturers in conjunction with the production of MelaFind^® components or materials; and

•

fees paid to third party data collection organizations and investigators in conjunction with the clinical trials and FDA and other regulatory review.

Deferred Rent

Deferred Rent

Stock-Based Compensation

Stock-Based Compensation

Income Tax Expense Estimates and Policies

Income Tax Expense Estimates and Policies

The Company accounts for income taxes using the asset and liability method for deferred income taxes.

Net Loss Per Common Share

Net Loss Per Common Share


	Year Ended December 31,
	2013		2012
Common stock options		3,065,714		2,426,533
Warrants		12,093,591		200,000
Restricted Stock Awards		99,375		—

Total		15,258,680		2,626,533

Comprehensive loss

Comprehensive loss

Litigation

Litigation

Fair Value Measurements

Fair Value Measurements

Warrant Liability

Warrant Liability

Recently Issued Accounting Standards

Recently Issued Accounting Standards

Management's Evaluation of Subsequent Events

Management’s Evaluation of Subsequent Events

Foreign Exchange

Foreign Exchange

Inventory (Tables)

12 Months Ended

Dec. 31, 2013

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following:


	December 31,
	2013			2012
MelaFind^® Systems	$	5,402		$	—
Mela record cards		328			333
Accessories		226			343

		5,956			676
Reserve for obsolete inventory		(325	)		—

	$	5,631		$	676

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2013

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment, at cost, consists of the following:


	December 31,						Estimated
	2013			2012			Useful Life		Useful Life
Leasehold improvements	$	906		$	906			Lease Term		Lease Term
Laboratory and research equipment		1,084			1,084			3-5 years		3-5 years
Office furniture and equipment		2,023			2,023			3-5 years		3-5 years
MelaFind^® Systems		5,081			6,306			3 years		3 years

		9,094			10,319
Accumulated depreciation and amortization		(5,403	)		(2,969	)

	$	3,691		$	7,350

Recurring Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2013

Fair Value Disclosures [Abstract]

Summary of Quantitative Information with Respect to Valuation Methodology and Significant Unobservable Inputs Used for Company's Warrant Liabilities


Black-Scholes Warrant Pricing	October 31, 2013			December 31, 2013
Stock Price	$	0.85		$	0.85
Risk-free Rate (5-year U.S. Treasury Yield)		1.31	%		1.75	%
Volatility (Annual)		94.78	%		93.43	%
Time to Maturity (Years)		5.50			5.33

Estimated Fair Values of Liabilities Measured on Recurring Basis

At December 31, 2013 and December 31, 2012, the estimated fair values of the liabilities measured on a recurring basis are as follows:


	Fair Value Measurements at December 31, 2013
	Balance at December 31, 2013		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Warrant derivative liabilities	$	3,017	$	—	$	—	$	3,017

Total	$	3,017	$	—	$	—	$	3,017

Fair Value Measurements at December 31, 2012

Balance at
December 31, 2012

Quoted Prices in
Active Markets
(Level 1)

Significant Other
Observable Inputs
(Level 2)

Significant
Unobservable Inputs
(Level 3)

Warrant derivative liabilities

—

Total

—

Liabilities Measured at Estimated Fair Value Using Unobservable Inputs

The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the years ended December 31, 2013 and 2012:


	Fair Value
	Measurements Using
	Significant
	Unobservable Inputs
	(Level 3)
	Warrant Derivative
	Liabilities
Beginning Balance at January 1, 2013	$	—
Issuance of warrants with derivative liabilities		3,373
Changes in estimated fair value		296
Reclassification of derivative liability to additional paid-in capital		(652	)

Ending balance at December 31, 2013	$	3,017

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References+ Details

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References+ Details

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2013

Equity [Abstract]

Schedule of Warrants Issued

As of December 31, 2013, the Company had the following warrants issued:


		Total
Issue Date	Holder	Warrants		Ex. Price
5/7/2009	Kingsbridge Capital Limited		200,000	$	11.35
4/26/2013	Hercules Technology Growth Capital		693,202	$	1.12
10/31/2013	Sabby Management, LLC “Series A”		6,857,142	$	0.85
10/31/2013	Sabby Management, LLC “Series B Prefunded Warrants”		4,343,247	$	0.70

			12,093,591

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Fair Value of Each Option Award Granted

The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation and assumptions as noted in the following table:


	December 31, 2013			December 31, 2012
Expected life		5-10 years			5-10 years
Expected volatility		72-77	%		74-80	%
Risk-free interest rate		0.71-2.45	%		0.91-1.60	%
Dividend yield		—			—

Schedule of Stock Option Plans

The status of the Company’s stock option plans during the periods indicated is summarized as follows:


						Weighted
						Average
				Weighted		Remaining
				Average		Contractual		Aggregate
	Number of			Exercise		Term in		Insintric
	Shares			Price		Years		Value
Outstanding at December 31, 2011		2,057,104			4.35		6.6

Granted		863,202			3.35		9.5
Exercised		(61,796	)		2.91
Forfeited or expired		(431,977	)		4.44

Outstanding at December 31, 2012		2,426,533			4.01		7.0	$	29

Granted		4,994,465			1.46		9.5
Exercised		(18,059	)		1.00				17
Forfeited or expired		(4,337,225	)		2.77				27

Outstanding at December 31, 2013		3,065,714			1.62		9.0

Vested and exercisable at December 31, 2013		1,261,355		$	2.56		8.1	$	—

Schedule of Stock Options Outstanding

The following table summarizes information about stock options outstanding at December 31, 2013:


	Options Outstanding						Options Exercisable
			Weighted-
			Average		Weighted-				Weighted-
			Remaining		Average				Average
	Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life		Price		Exercisable		Price
$0.65-$3.00		2,412,651		9.65 years	$	0.89		694,742	$	1.17
$3.01-$6.00		500,513		7.72 years		3.40		441,038		3.38
$6.01-$10.35		152,550		3.35 years		7.28		125,575		7.38

$0.65-$10.35		3,065,714		9.02 years	$	1.62		1,261,355	$	2.56

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

Computation of U.S. Federal Income Tax Rate to Pretax Loss From Continuing Operations

The difference between the actual income tax benefit and that computed by applying the U.S. federal income tax rate of 34% to pretax loss from continuing operations is summarized below:


	For the years ended December 31,
	2013			2012
Computed expected tax benefit	$	(8,822	)	$	(7,709	)
State tax benefit, net of federal effect		(1,557	)		(1,360	)
Increase in the valuation allowance		10,379			9,069

Provision for income taxes	$	—		$	—

Summary of Deferred Tax Assets and Liabilities

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2013 and 2012 are as follows:


	December 31,
	2013			2012
Deferred tax assets:
Net operating loss carryforward	$	35,086		$	26,471
Capitalized research and developmental costs		27,794			26,511
Non-cash compensation		3,681			3,200

Total deferred tax assets		66,561			56,182
Less valuation allowance		(66,561	)		(56,182	)

Net deferred tax assets	$	—		$	—

Company - Additional Information (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	0 Months Ended	12 Months Ended		0 Months Ended
	Aug. 22, 2013	Dec. 31, 2013	Dec. 31, 2012	Feb. 19, 2014 Subsequent Event [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash used in operating activities		$ (19,413)	$ (19,224)
Net revenues		$ 536	$ 278
Number of consecutive business days, non-compliance of minimum bid price	30 days
Minimum bid price	$ 1.00
Grace period granted by NASDAQ to regain compliance	180 days
Additional grace period				180 days

Basis of Presentation - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	1 Months Ended		12 Months Ended			1 Months Ended	12 Months Ended
	Oct. 31, 2013	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Feb. 28, 2014 Subsequent Event [Member]	Dec. 31, 2013 Subsequent Event [Member]	Dec. 31, 2013 First Quarter of 2014 [Member]
Liquidity And Managements Plans [Line Items]
Net proceeds from issuance of common stock and warrants	$ 5,500
Net proceeds from the sale of convertible preferred stock, common stock and warrants						11,500
Payment made to lender		6,400
Accumulated deficit			(168,148)	(142,200)
Net loss			(25,948)	(22,673)
Working capital			4,699
Cash and cash equivalents			3,783	7,862	27,997
Convertible preferred stock and warrants							12,300
Liquidated damages								2,460
Additional liquidated damages								$ 1,476

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013 Segment	Dec. 31, 2012	Oct. 31, 2013
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Liquid investment maturity period	Three months or less
Reserve for obsolete inventory	$ 325,000	$ 0
Inventory, Gross	5,956,000	676,000
Number of segments operated by the company	1
Associated revenue over the related service period	Generally expected to be two years
Property and equipment, capitalization cost	5,188,000	6,158,000
Depreciation expense	2,434,000	957,000
Deferred financing costs		106,000
Uncertain tax positions	0
Tax benefits to be recognized on likelihood of being realized upon ultimate resolution	Greater than fifty percent
Open tax year subject to examination	2009
Comprehensive income (loss)	0
Warrants issued to purchase common stock			6,857,142
MelaFind Systems [Member]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Inventory, Gross	$ 5,402,000
Minimum [Member]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of related assets	3 years
Maximum [Member]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of related assets	5 years
Patents and Trademarks [Member]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Useful life of patents or trademark	15 years

Summary of Significant Accounting Policies - Schedule of Stock Options, Warrants and Restricted Stock Awards (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	15,258,680	2,626,533
Common Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	3,065,714	2,426,533
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	12,093,591	200,000
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	99,375

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Inventory - Schedule of Inventory (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventory [Line Items]
Inventory, Gross	$ 5,956	$ 676
Reserve for obsolete inventory	(325)	0
Inventory, Net	5,631	676
MelaFind Systems [Member]
Inventory [Line Items]
Inventory, Gross	5,402
Mela Record Cards [Member]
Inventory [Line Items]
Inventory, Gross	328	333
Accessories [Member]
Inventory [Line Items]
Inventory, Gross	$ 226	$ 343

Property and Equipment - Summary of Property and Equipment (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Gross	$ 9,094	$ 10,319
Accumulated depreciation and amortization	(5,403)	(2,969)
Net	3,691	7,350
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross	906	906
Estimated useful life of leasehold improvements	Lease Term
Laboratory and Research Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross	1,084	1,084
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross	2,023	2,023
MelaFind Systems [Member]
Property, Plant and Equipment [Line Items]
Gross	$ 5,081	$ 6,306
Estimated Useful Life	3 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Minimum [Member] \| Laboratory and Research Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Minimum [Member] \| Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Maximum [Member] \| Laboratory and Research Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Maximum [Member] \| Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years

Property and Equipment - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 2,434	$ 957
Inventory, Gross	5,956	676
MelaFind Systems [Member]
Property, Plant and Equipment [Line Items]
Impairment charge	1,011
Description of user agreements expire period	User agreements expire over the next 2 years
Inventory, Gross	$ 5,402

Patents and Trademarks - Additional Information (Detail) (Patents and Trademarks [Member], USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization, net	$ 232	$ 227
Amortization expense related to all patents	6	12
Amortization expense of currently held patents for the year 2014	5
Amortization expense of currently held patents for the year 2015	5
Amortization expense of currently held patents for the year 2016	5
Amortization expense of currently held patents for the year 2017	5
Amortization expense of currently held patents for the year 2018	$ 5

Commitments and Contingencies - Schedule of Approximate Aggregate Minimum Future Payments (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]
2014	$ 478
2015	478
2016	477
TOTAL	$ 1,433

Debt - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	0 Months Ended	1 Months Ended	12 Months Ended		12 Months Ended			0 Months Ended	12 Months Ended
	Sep. 10, 2013	Oct. 31, 2013	Dec. 31, 2013	Mar. 15, 2013	Dec. 31, 2013 Warrant Obligation [Member]	Dec. 31, 2013 Warrant Obligation [Member] Minimum [Member]	Dec. 31, 2013 Warrant Obligation [Member] Maximum [Member]	Mar. 15, 2013 Hercules Technology Growth Capital Inc. [Member]	Dec. 31, 2013 Hercules Technology Growth Capital Inc. [Member]	Sep. 10, 2013 Hercules Technology Growth Capital Inc. [Member]
Debt Instrument [Line Items]
Loan payable								$ 6,000
Accrued interest rate								10.45%
Maturity period of loan								42 months
Time period of interest payment								First 12 months
Prepayment of loan										6,400
Term fee										425
Warrants issued to purchase common stock		6,857,142						693,202
Warrants issued to purchase common stock, exercise price								1.12
Expiry date for warrant outstanding									Apr. 26, 2018
Warrant issuance date									Apr. 25, 2013
Fair value of warrant obligation				563
Initial carrying value of the loan				5,300
Changes in fair value of warrants			296		90
Stock prices						$ 1.16	$ 1.18
Volatility		94.78%	93.43%		77.00%
Maturity period		5 years 6 months	5 years 3 months 29 days		5 years
Exercise prices		$ 0.85	$ 0.85			$ 1.15	$ 1.16
Risk free interest rate of return		1.31%	1.75%		0.84%
Change in underlying unobservable inputs					10.00%
Initial loan discount amount			727
Loss on early extinguishment of debt	$ 983

Recurring Fair Value Measurements - Summary of Quantitative Information with Respect to Valuation Methodology and Significant Unobservable Inputs Used for Company's Warrant Liabilities (Detail) (USD $)	1 Months Ended	12 Months Ended
	Oct. 31, 2013	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Stock Price	$ 0.85	$ 0.85
Risk-free Rate	1.31%	1.75%
Volatility (Annual)	94.78%	93.43%
Time to maturity (Years)	5 years 6 months	5 years 3 months 29 days

Recurring Fair Value Measurements - Estimated Fair Values of Liabilities Measured on Recurring Basis (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 3,017
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	3,017
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities
Quoted Prices in Active Markets (Level 1) [Member] \| Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities
Significant Other Observable Inputs (Level 2) [Member] \| Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	3,017
Significant Unobservable Inputs (Level 3) [Member] \| Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 3,017

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References+ Details

Recurring Fair Value Measurements - Liabilities Measured at Estimated Fair Value Using Unobservable Inputs (Detail) (USD $) In Thousands, unless otherwise specified					12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013 Warrant [Member]	Dec. 31, 2013 Significant Unobservable Inputs (Level 3) [Member]	Dec. 31, 2012 Significant Unobservable Inputs (Level 3) [Member]	Dec. 31, 2013 Significant Unobservable Inputs (Level 3) [Member] Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	$ 3,017	$ 3,017	$ 3,017
Issuance of warrants with derivative liabilities					3,373
Changes in estimated fair value					296
Reclassification of derivative liability to additional paid-in capital					(652)
Ending Balance	$ 3,017	$ 3,017	$ 3,017		$ 3,017

- Definition

+ References+ Details

Stockholders' Equity - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended				3 Months Ended	12 Months Ended			0 Months Ended	12 Months Ended		0 Months Ended		1 Months Ended	0 Months Ended
	Dec. 31, 2013	Oct. 31, 2013	Oct. 29, 2013	Dec. 31, 2012	Dec. 31, 2013 ATM Program [Member]	Dec. 31, 2013 ATM Program [Member]	Feb. 12, 2013 Shelf Registration Statement [Member]	Dec. 31, 2013 Securities Purchase Agreement [Member]	Oct. 29, 2013 Series A Warrants [Member]	Dec. 31, 2013 Series A Warrants [Member]	Oct. 29, 2013 Series B Warrants [Member]	Mar. 15, 2013 Hercules Technology Growth Capital Inc. [Member]	Feb. 05, 2014 Subsequent Event [Member]	Jan. 31, 2014 Subsequent Event [Member]	Feb. 05, 2014 Subsequent Event [Member] Series A Convertible Preferred Stock [Member]	Feb. 05, 2014 Subsequent Event [Member] Series A Preferred Stock [Member]
Securities Financing Transaction [Line Items]
Preferred stock, shares authorized	10,000,000			10,000,000
Preferred stock, par value	$ 0.10			$ 0.10
Preferred stock, shares issued	0			0											12,300
Preferred stock, shares outstanding	0			0
Preferred stock, par value															$ 0.10
Preferred stock stated value, per share															$ 1,000
Preferred stock converted to common stock, shares															14,642,857
Preferred stock converted to common stock, conversion price															$ 0.84
Warrants issued to purchase common stock															13,297,297
Proceeds from issuance of warrants															$ 12,300
Warrants issued to purchase common stock, exercise price									0.85			1.12			0.74
Warrants issued, exercisable term															5 years
Preferred stock voting rights, description													In connection with the financing, Broadfin Capital, LLC has been granted the right to designate one director to our Board of Directors, so as long as it retains 30% of its investment in the Series A Preferred Stock (or the shares of common stock underlying the Series A Preferred Stock) or holds any warrants, and the Purchasers have been granted rights of participation in future offerings of our securities for one year.
Percentage of preferred stock investment																30.00%
Common stock purchased, shares														202,703
Common stock purchased, share price														$ 0.74
Proceeds from common stock purchased														150,000
Common stock, shares authorized	95,000,000			95,000,000
Common stock, par value	$ 0.001			$ 0.001
Sales agreement termination date						Feb. 15, 2013
Number of common stock issued through company ATM program					4,700,000	6,600,000
Gross proceeds from sale of common stock					8,800	14,400
Net proceeds from sale of common stock					8,500	13,800
Public offering of common stock shares under underwriting agreement							6,100,000
Initial public offering price per share							$ 1.30
Gross proceeds from sale of common stock							7,900
Net proceeds from sale of common stock							7,300
Warrants issued to purchase common stock												693,202
Warrants expiration period												5 years
Common stock issued	47,501,596		4,228,181	32,204,720
Warrants issued to purchase common stock		6,857,142							6,857,142		4,343,247
Proceeds from issuance of common stock and warrants									6,000
Warrants exercisable date									May 01, 2014
Warrants expiry date									May 01, 2019
Offering closed date								Oct. 31, 2013
Change in fair value of warrant liability	$ 296									$ 205

Stockholders' Equity - Schedule of Warrants Issued (Detail)	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Total Warrants	12,093,591
Kingsbridge Capital Limited [Member]
Class of Warrant or Right [Line Items]
Issue Date	May 07, 2009
Total Warrants	200,000
Ex. Price	11.35
Hercules Technology Growth Capital [Member]
Class of Warrant or Right [Line Items]
Issue Date	Apr. 26, 3013
Total Warrants	693,202
Ex. Price	1.12
Sabby Management, LLC "Series A" [Member]
Class of Warrant or Right [Line Items]
Issue Date	Oct. 31, 2013
Total Warrants	6,857,142
Ex. Price	0.85
Sabby Management, LLC "Series B Prefunded Warrants" [Member]
Class of Warrant or Right [Line Items]
Issue Date	Oct. 31, 2013
Total Warrants	4,343,247
Ex. Price	0.70

Stock-Based Compensation - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	0 Months Ended	12 Months Ended
	Apr. 25, 2013	Dec. 31, 2013	Dec. 31, 2012	Feb. 11, 2013	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants		3,729,853
Expiry period of option plan		10 years
Number of granted shares		4,994,465	863,202
Compensation expense recognized for stock option		$ 1,301	$ 1,488
Cash received from options and warrants exercised		18	45
Expected dividend yield
Number of stock options to purchase		3,065,714
Common stock at exercise prices range, minimum		$ 0.65
Common stock at exercise prices range, maximum		$ 10.35
Total options outstanding		1,261,355	1,620,320
Weighted Average Exercise Price per Share Vested and exercisable		$ 2.56	$ 3.99
Total intrinsic value of options exercisable		0
Weighted average fair value of options granted		$ 0.60	$ 2.28
Total intrinsic value of options exercised		17	86
Requisite service periods for options granted for employees		4 years	4 years
Requisite service periods for options granted to directors		1 year	1 year
Total options outstanding		3,065,714	2,426,533		2,057,104
Options nonvested		1,804,359
Total unrecognized compensation cost related to unvested options		755
Total unrecognized compensation cost to be recognized over the requisite service period		447
Fully vested options				900,000
Fully vested options lapsed	900,000
Fully vested options lapsing exercise restriction date		Apr. 25, 2013
Additional stock compensation recognized	423
2013 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants		3,500,000
2005 and 2013 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate shares of common stock available for grant		3,729,853
2005 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of granted shares		7,224,028
Performance Milestones [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vested upon the attainment of milestone		650,850
Total unrecognized compensation cost		$ 308

Stock-Based Compensation - Schedule of Fair Value of Each Option Award Granted (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility - Minimum	72.00%	74.00%
Expected volatility - Maximum	77.00%	80.00%
Risk-free interest rate - Minimum	0.71%	0.91%
Risk-free interest rate - Maximum	2.45%	1.60%
Dividend yield
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	5 years	5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	10 years	10 years

Stock-Based Compensation - Schedule of Stock Option Plans (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Outstanding, Beginning	2,426,533	2,057,104
Number of Shares Granted	4,994,465	863,202
Number of Shares Exercised	(18,059)	(61,796)
Number of Shares Forfeited or expired	(4,337,225)	(431,977)
Number of Shares Outstanding, Ending	3,065,714	2,426,533	2,057,104
Number of Shares Vested and exercisable	1,261,355
Weighted Average Exercise Price per Share Outstanding, Beginning	$ 1.62	$ 4.01	$ 4.35
Weighted Average Exercise Price per Share Granted		$ 1.46	$ 3.35
Weighted Average Exercise Price per Share of options Exercised		$ 1.00	$ 2.91
Weighted Average Exercise Price per Share Forfeited or expired		$ 2.77	$ 4.44
Weighted Average Exercise Price per Share Outstanding, Ending		$ 1.62	$ 4.01	$ 4.35
Weighted Average Exercise Price per Share Vested and exercisable	$ 2.56	$ 3.99
Weighted Average Remaining Contractual Term in Years Granted		9 years 6 months	9 years 6 months
Weighted Average Remaining Contractual Term in Years Vested and exercisable	8 years 1 month 6 days
Weighted Average Remaining Contractual Term in Years Outstanding		9 years	7 years	6 years 7 months 6 days
Aggregate Intrinsic Value Outstanding Vested and exercisable	$ 0
Aggregate Intrinsic Value Outstanding		29
Aggregate Intrinsic Value for Exercised		17
Aggregate Intrinsic Value for Forfeited or expired		$ 27

Stock-Based Compensation - Schedule of Stock Options Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 0.65
Range of Exercise Prices, Upper Range Limit	$ 10.35
Options Exercisable, Number Exercisable	3,065,714
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 0.65
Range of Exercise Prices, Upper Range Limit	$ 3.00
Options Outstanding, Number Outstanding	2,412,651
Options Outstanding, Weighted-Average Remaining Contractual Life	9 years 7 months 24 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.89
Options Exercisable, Number Exercisable	694,742
Options Exercisable, Weighted-Average Exercise Price	$ 1.17
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 3.01
Range of Exercise Prices, Upper Range Limit	$ 6.00
Options Outstanding, Number Outstanding	500,513
Options Outstanding, Weighted-Average Remaining Contractual Life	7 years 8 months 19 days
Options Outstanding, Weighted-Average Exercise Price	$ 3.40
Options Exercisable, Number Exercisable	441,038
Options Exercisable, Weighted-Average Exercise Price	$ 3.38
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 6.01
Range of Exercise Prices, Upper Range Limit	$ 10.35
Options Outstanding, Number Outstanding	152,550
Options Outstanding, Weighted-Average Remaining Contractual Life	3 years 4 months 6 days
Options Outstanding, Weighted-Average Exercise Price	$ 7.28
Options Exercisable, Number Exercisable	125,575
Options Exercisable, Weighted-Average Exercise Price	$ 7.38
Net Range [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 0.65
Range of Exercise Prices, Upper Range Limit	$ 10.35
Options Outstanding, Number Outstanding	3,065,714
Options Outstanding, Weighted-Average Remaining Contractual Life	9 years 7 days
Options Outstanding, Weighted-Average Exercise Price	$ 1.62
Options Exercisable, Number Exercisable	1,261,355
Options Exercisable, Weighted-Average Exercise Price	$ 2.56

Related Party Agreements - Additional Information (Detail) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2013 Consulting Agreement with Gerald Wagner, Ph.D [Member]	Dec. 31, 2012 Consulting Agreement with Gerald Wagner, Ph.D [Member]	Mar. 11, 2014 Transition Services Provided by Robert Coradini [Member] Subsequent Event [Member]
Related Party Transaction [Line Items]
Monthly retaining fee	$ 2,500
Additional retaining fee	2,500
Amount paid under consulting agreement	0	30,000
Consulting agreement termination date	Dec. 31, 2012
Service fee			$ 48,000

Income Taxes - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
U.S. federal income tax rate	34.00%
Increase in the valuation allowance	$ 10,379	$ 9,069
Net operating loss carryforwards	$ 87,000
Tax positions more likely than not threshold	50.00%
Tax benefit recognition, description	Tax positions that meet the more likely than not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority.

Income Taxes - Computation of U.S. Federal Income Tax Rate to Pretax Loss From Continuing Operations (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Computed expected tax benefit	$ (8,822)	$ (7,709)
State tax benefit, net of federal effect	(1,557)	(1,360)
Increase in the valuation allowance	10,379	9,069
Provision for income taxes

Income Taxes - Summary of Deferred Tax Assets and Liabilities (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:
Net operating loss carryforward	$ 35,086	$ 26,471
Capitalized research and developmental costs	27,794	26,511
Non-cash compensation	3,681	3,200
Total deferred tax assets	66,561	56,182
Less valuation allowance	(66,561)	(56,182)
Net deferred tax assets

Subsequent Events - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended		12 Months Ended				0 Months Ended		1 Months Ended	12 Months Ended	0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013 First Two Events [Member]	Dec. 31, 2013 Third Event [Member]	Dec. 31, 2013 Fourth Event [Member]	Dec. 31, 2013 Next Two (Fifth and Sixth) Event [Member]	Feb. 19, 2014 Subsequent Event [Member]	Feb. 05, 2014 Subsequent Event [Member]	Jan. 31, 2014 Subsequent Event [Member]	Dec. 31, 2013 Subsequent Event [Member]	Feb. 05, 2014 Subsequent Event [Member] Series A Convertible Preferred Stock [Member]	Feb. 05, 2014 Subsequent Event [Member] Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares issued	0	0									12,300
Preferred stock, par value											$ 0.10
Preferred stock stated value, per share											$ 1,000
Preferred stock converted to common stock, shares											14,642,857
Preferred stock converted to common stock, conversion price											$ 0.84
Warrants issued to purchase common stock											13,297,297
Proceeds from issuance of warrants											$ 12,300
Warrants issued, exercise price											0.74
Warrants issued, exercisable term											5 years
Preferred stock voting rights, description								In connection with the financing, Broadfin Capital, LLC has been granted the right to designate one director to our Board of Directors, so as long as it retains 30% of its investment in the Series A Preferred Stock (or the shares of common stock underlying the Series A Preferred Stock) or holds any warrants, and the Purchasers have been granted rights of participation in future offerings of our securities for one year.
Percentage of preferred stock investment												30.00%
Common stock purchased, shares									202,703
Common stock purchased, share price									$ 0.74
Proceeds from common stock purchased									150,000
Aggregate purchase price paid by Purchaser	32.00%		10.00%	7.50%	2.50%	1.00%
Number of trading days to file registration statement										17 days
Initial re-sale registration statement closure date										Feb. 25, 2014
Initial re-sale effective declaration date										Mar. 07, 2014
Liquidation damages paid										$ 2,460
Additional grace period							180 days
Additional grace period granted date							Aug. 18, 2014

Statement of Stockholders' Equity (Parenthetical) (Common Stock [Member], USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Common Stock [Member]
Issuance costs of common stock in connection with Public Offering	$ 1,025	$ 282
Issuance costs of common stock and warrants	$ 3,426

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	8. Employee Benefit Plan The Company had a SIMPLE IRA defined contribution plan covering all qualified employees. An officer of the Company served as trustee of the plan. The Company provided a matching contribution of up to 3% of each employee’s salary. Company contributions to this plan amounted to approximately $136 and $151 for the years ended December 31, 2013 and 2012, respectively. On December 31, 2013 the Company ceased contributions and terminated the plan.

Employee Benefit Plan - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Compensation And Retirement Disclosure [Abstract]
Amount of company contributions	$ 136	$ 151
Percentage of contribution by the company of each employee salary	3.00%

Restructuring Charge - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]
Employee termination benefits	$ 100
Cost of Revenue, Research and Development and Selling General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Employee termination benefits	$ 100

Recurring Fair Value Measurements - Summary of Quantitative Information with Respect to Valuation Methodology and Significant Unobservable Inputs Used for Company's Warrant Liabilities (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]
U.S Treasury Yield, period	5 years